Breakout Stocks –  Corona Virus Stocks –  Top Mining Stocks  – Best Med Stocks





Target $6 – $8


$15 Mill Raise

These shares hit a 52 week high earlier this year hitting $4.25 before consolidating to current levels .Revenues are projected to double. Volume has begun to increase signaling additional investor interest in these shares .Climb aboard this train .

We look for an upside BREAKOUT to take these shares to the $6-$8 level  based upon Maxim Research projections

Serious investors should place these shares on their BUY LIST 

Biotricity: Capital Raise Leads To Buying Opportunity

  • BTCY recently announced a capital raise, leading to a sudden and significant decrease in the share price.
  • With likely catalysts ahead, and continued stellar growth in its core business, the recent share price drop presents a compelling buying opportunity.
  • In conjunction with the secondary offering, BTCY has now been uplisted to Nasdaq, providing more visibility and liquidity in the stock.
  • Anapp currently under development by BTCY could blow the top off all current management guidance and analyst estimates.
  • While there are certainly risks, the stock could conceivably double over the next year.

More Info Contact

Gary Zwetchkenbaum

Plum Tree Consulting LLC

Cell (516)455-7662

Biotricity Completes Nasdaq Listing

Closes $15 Million Underwritten Public Offering

REDWOOD CITY, CA / ACCESSWIRE / August 30, 2021 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the closing of an underwritten public offering of 5,000,000 shares of common stock of the Company for total gross proceeds to the Company of approximately $15 million. The offering was priced at $3.00 per share. In addition, the Company has granted the underwriter of the offering a 30-day option to purchase an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital, potential acquisitions, and other business opportunities.In connection with the offering the Company’s common stock, on August 26, 2021 the Company common stock was listed on the Nasdaq Capital Market under the symbol “BTCY”.

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

This offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-255544) previously filed with the Securities and Exchange Commission on April 27, 2021 and declared effective on May 4, 2021. The shares were offered by Biotricity only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. A final prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and will be available on the SEC’s website located at Electronic copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting H.C. Wainwright & Co. LLC at: 430 Park Avenue 3rd Floor, New York, NY 10022, by email at, or by telephone at (646) 975-6996.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Biotricity Inc.

Biotricity (NASDAQ:BTCY) is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.d. Writer not paid